Anavex Life Sciences Corp (AVXL)

[crescentmotor]

The distinction between the subgroups wasn't known at the time the trial was designed.

The bashers on the board always want to take the discussion to the subgroups matter because of they believe the lack of pre-specification casts a shadow on the trial's results. It doesn't really affect Blarcamesine's chances for approval since the original data reported out of the 48 week trial passed the threshold for both sufficient safety and efficacy. As to the subgroups and the OLE data, that is extremely positive in that it adds additional confirmatory information to the blinded trial data that was already compelling.